Naloxegol (BioDeep_00000837563)
代谢物信息卡片
化学式: C34H53NO11 (651.3618428)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COCCOCCOCCOCCOCCOCCOCCOC1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC=C)O
InChI: InChI=1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3/t28-,29+,32-,33-,34+/m0/s1
描述信息
A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation > A06AH - Peripheral opioid receptor antagonists
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists
C78272 - Agent Affecting Nervous System > C681 - Opiate Antagonist
D013501 - Surface-Active Agents > D011092 - Polyethylene Glycols
D001697 - Biomedical and Dental Materials
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:82975
- KEGGdrug: D10479
- PubChem: 56959087
- DrugBank: DB09049
- ChEMBL: CHEMBL2219418
- CAS: 854601-70-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Milad Bagheri, Ahmadreza Niavarani. Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding.
Journal of biomolecular structure & dynamics.
2022 03; 40(4):1597-1606. doi:
10.1080/07391102.2020.1830854. [PMID: 33030105] - Mehran Haidari, Sravan Mansani, Dezaray Ponds, Lissett Romero, Saad Alsaab. Consumption of Movantik™ (Naloxegol) results in detection of naloxone in the patient's urine evaluated by confirmatory urine drug testing.
Clinical biochemistry.
2019 May; 67(?):48-53. doi:
10.1016/j.clinbiochem.2019.03.006. [PMID: 30890414] - Justin Wotring, Sky Countryman, Frank N Wallace, Erin C Strickland, Oneka T Cummings, Gregory L McIntire. Movantik™ and the Frequency of Positive Naloxone in Urine.
Journal of analytical toxicology.
2018 04; 42(3):e38-e40. doi:
10.1093/jat/bkx104. [PMID: 29301016] - Khanh Bui, Bruce Birmingham, Ulysses Diva, Bruce Berger. An Open-Label, Randomized Bioavailability Study of Alternative Methods of Oral Administration of Naloxegol in Healthy Subjects.
Clinical pharmacology in drug development.
2017 07; 6(4):420-427. doi:
10.1002/cpdd.335. [PMID: 28127938] - Khanh Bui, Diansong Zhou, Hongmei Xu, Eike Floettmann, Nidal Al-Huniti. Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist.
Clinical pharmacokinetics.
2017 06; 56(6):573-582. doi:
10.1007/s40262-016-0479-z. [PMID: 28035588] - Yan Li, Mark Hoffmann, Paul Severin. Determination of naloxegol in human biological matrices.
Bioanalysis.
2017 Apr; 9(8):609-619. doi:
10.4155/bio-2016-0253. [PMID: 28504549] - Nidal Al-Huniti, Sunny Chapel, Hongmei Xu, Khanh H Bui, Mark Sostek. Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients.
British journal of clinical pharmacology.
2016 Jan; 81(1):89-100. doi:
10.1111/bcp.12756. [PMID: 26317320] - Michael A Eldon, Alan R Kugler, Robert A Medve, Khanh Bui, Kathleen Butler, Mark Sostek. Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol.
Clinical pharmacology in drug development.
2015 11; 4(6):442-8. doi:
10.1002/cpdd.204. [PMID: 27137716] - Khanh Bui, Fahua She, Michael Hutchison, Åsa Brunnström, Mark Sostek. Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects.
International journal of clinical pharmacology and therapeutics.
2015 Oct; 53(10):838-46. doi:
10.5414/cp202276. [PMID: 26329350] - Khanh Bui, Fahua She, Mark Sostek. The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol.
Journal of clinical pharmacology.
2014 Dec; 54(12):1368-74. doi:
10.1002/jcph.348. [PMID: 24945932] - Khanh Bui, Fahua She, Mark Sostek. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol.
Journal of clinical pharmacology.
2014 Dec; 54(12):1375-82. doi:
10.1002/jcph.349. [PMID: 24946021]